Scholar Rock Holding (SRRK) Directors and Executive Officers

Officers & Directors

Jeffrey S. Flier
Director

David Hallal
Chairman of the Board of Directors

Kristina Burow
Director

Amir Nashat
Director

Akshay Vaishnaw
Director

Katie Peng
Director

Joshua Reed
Director

Jay T. Backstrom
President and Chief Executive Officer (Principal Executive Officer)

Richard Brudnick
Director

Srinivas Akkaraju
Director

Edward H. Myles
Chief Operating Officer

Michael Gilman
Director ,

Scholar Rock Holding Corp currently has 289 employees.

News about Scholar Rock Holding Corp Key Personnel

Late-stage Biopharmaceutical Company Scholar Rock Faces Scrutiny Over Inducement Grants Amidst Financial Struggles

Scholar Rock’s Recent Inducement Grants Questioned Amidst Financial Struggles
By
In a recent announcement, late-stage biopharmaceutical company Scholar Rock (NASDAQ: SRRK) revealed that it granted inducement equity awards to six newly hired employees, covering a total of 201,469 shares of its common stock. This move comes at a time when the company’s financial status raises concerns, with a cumulative net loss of $-159 million in the twelve months ending in the third quarter of 2023. Scholar Rock s negative return on investment (ROI) of -60.05% only adds to the growing apprehension surrounding the firm s stability.
The inducement grants provided to new employees are reported to be under th...

Scholar Rock's Resilience Shown Through Board Appointments and Financial Transformations

In a recent announcement, Scholar Rock, a pioneering biopharmaceutical company focused on innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases, revealed the addition of Katie Peng to its Board of Directors and the promotion of Mo Qatanani, Ph.D., as Chief Scientific Officer. These developments have significant implications for the company s future and prospects in the biopharmaceutical industry.
Katie Peng s appointment to Scholar Rock s Board of Directors brings fresh expertise and perspectives as the company navigates the challenges of developing cutting-edge treatments. Peng s wealth of experience in the biotech industry will contribute to...